Skip NavigationSkip to Content
Return Return to Search Results

Novel cancer gene variants and gene fusions of triple-negative breast cancers (TNBCs) reveal their molecular diversity conserved in the patient-derived xenograft (PDX) model

  1. Author:
    Jung, Jaeyun
    Jang, Kiwon
    Ju, Jung Min
    Lee, Eunji
    Lee, Jong Won
    Kim, Hee Jung
    Kim, Jisun
    Lee, Sae Byul
    Ko, Beom Seok
    Son, Byung Ho
    Lee, Hee Jin
    Gong, Gyungyup
    Ahn, Sei Yeon
    Choi, Jung Kyoon
    Singh, Shree Ram
    Chang, Suhwan

  2. Author Address

    Department of Biomedical Sciences, University of Ulsan School of Medicine, Asan Medical Center, Seoul, 05505, Republic of Korea; Department of Pathology, University of Ulsan School of Medicine, Asan Medical Center, Seoul, 05505, Republic of Korea., Department of Bio and Brain Engineering, KAIST, University of Ulsan School of Medicine, Asan Medical Center, Seoul, 05505, Republic of Korea., Department of Biomedical Sciences, University of Ulsan School of Medicine, Asan Medical Center, Seoul, 05505, Republic of Korea., Department of Surgery, University of Ulsan School of Medicine, Asan Medical Center, Seoul, 05505, Republic of Korea., Basic Research Laboratory, Stem Cell Regulation and Animal Aging Section, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA. Electronic address: suhwan.chang@amc.seoul.kr., Department of Biomedical Sciences, University of Ulsan School of Medicine, Asan Medical Center, Seoul, 05505, Republic of Korea. Electronic address: singhshr@mail.nih.gov.,
    1. Year: 2018
    2. Date: Aug 01
    3. Epub Date: 2018 04 20
  2. Journal: Cancer Letters
    1. 428
    2. Pages: 127-138
  4. Type of Article: Article
  1. Abstract:

    Despite the improved 5-year survival rate of breast cancer, triple-negative breast cancer (TNBC) remains a challenge due to lack of effective targeted therapy and higher recurrence and metastasis than other subtypes. To identify novel druggable targets and to understand its unique biology, we tried to implement 24 patient-derived xenografts (PDXs) of TNBC. The overall success rate of PDX implantation was 45%, much higher than estrogen receptor (ER)-positive cases. Immunohistochemical analysis revealed conserved ER/PR/Her2 negativity (with two exceptions) between the original and PDX tumors. Genomic analysis of 10 primary tumor-PDX pairs with Ion AmpliSeq CCP revealed high degree of variant conservation (85.0% to 96.9%) between primary and PDXs. Further analysis showed 44 rare variants with a predicted high impact in 36 genes including Trp53, Pten, Notch1, and Col1a1. Among them, we confirmed frequent Notch1 variant. Furthermore, RNA-seq analysis of 24 PDXs revealed 594 gene fusions, of which 163 were in-frame, including AZGP1-GJC3 and NF1-AARSD1. Finally, western blot analysis of oncogenic signaling proteins supporting molecular diversity of TNBC PDXs. Overall, our report provides a molecular basis for the usefulness of the TNBC PDX model in preclinical study. Copyright © 2018. Published by Elsevier B.V.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.canlet.2018.04.020
  3. PMID: 29684420
  4. View record in Web of Science®
  5. WOS: 000435058600012
  6. PII : S0304-3835(18)30287-8

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel